|Calculated MW||65 kDa, homodimer, glycosylated|
|Other Names||SYM1, SYNS1, NOG.|
|Source||Human 293 cell expressed|
|Assay&Purity||SDS-PAGE; > 95%|
|Results||20 to 100 ng/ml|
|Application Notes||Reconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.|
|Storage||-80°C; Lyophilized in PBS.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Noggin belongs to a group of diffusible proteins which bind to ligands of the TGF-β family and regulate their activity by inhibiting their access to signaling receptors. Noggin was originally identified as a BMP-4 antagonist whose action is critical for proper formation of the head and other dorsal structures. Consequently, Noggin has been shown to modulate the activities of other BMPs including BMP-2,-7,-13, and -14. Targeted deletion of Noggin in mice results in prenatal death and recessive phenotype displaying a severely malformed skeletal system. Conversely, transgenic mice over-expressing Noggin in mature osteoblasts display impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis.
Valenzuela D.M.,et al.J. Neurosci. 15:6077-6084(1995).
Groppe J.,et al.Nature 420:636-642(2002).
Gong Y.,et al.Nat. Genet. 21:302-304(1999).
Takahashi T.,et al.Clin. Genet. 60:447-451(2001).
Dixon M.E.,et al.Genet. Med. 3:349-353(2001).
If you have any additional inquiries please email technical services at email@example.com.